Clinical trial • Phase I • Neurology
IMU-838 for Multiple sclerosis
Phase I trial of IMU-838 for Multiple sclerosis. None/Not specified-controlled. 26 participants.
Overview
- Trial Therapeutic Area
- Neurology
- Trial Disease
- Multiple sclerosis
- Trial Stage
- Phase I
Key dates
- Initial CTIS Submission Date
- 03-02-2026
- First CTIS Authorization Date
- 16-03-2026
Trial design
None/Not specified-controlled Phase I trial across 1 site in Belgium.
- Comparator
- None/Not specified
- Target Sample Size
- 26
Recruitment
- Planned Sample Size
- 26
- Recruitment Window Months
- 4
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 26
Belgium
- Earliest CTIS Part Ii Submission Date
- 26-02-2026
- Latest Decision Or Authorization Date
- 16-03-2026
- Processing Time Days
- 18
- Number Of Sites
- 1
- Number Of Participants
- 26
Sites
- Site Name
- SGS Belgium
- Department Name
- CPU
- Contact Person Name
- Frédéric Vanhoutte
- Contact Person Email
- Frederic.Vanhoutte@sgs.com
- Number Of Participants
- 26
Sponsor
Primary sponsor
- Full Name
- Immunic AG
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- Germany
Investigational products
- Investigational Product Name
- IMU-838
- Combination Treatment
- Yes
Related trials
Other published trials that may interest you.